These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16718469)

  • 1. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089.
    Zhang X; Jiang F; Li P; Li C; Ma Q; Nicosia SV; Bai W
    Clin Cancer Res; 2005 Jan; 11(1):323-8. PubMed ID: 15671562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal paclitaxel in the management of ovarian cancer.
    Markman M
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
    Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
    El Hilali N; Rubio N; Blanco J
    Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.
    Jang SH; Wientjes MG; Au JL
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1035-42. PubMed ID: 11181938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
    Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
    Ohashi N; Kodera Y; Nakanishi H; Yokoyama H; Fujiwara M; Koike M; Hibi K; Nakao A; Tatematsu M
    Int J Oncol; 2005 Sep; 27(3):637-44. PubMed ID: 16077911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
    Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
    Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
    Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
    Bao R; Selvakumaran M; Hamilton TC
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.
    Safavy A; Georg GI; Vander Velde D; Raisch KP; Safavy K; Carpenter M; Wang W; Bonner JA; Khazaeli MB; Buchsbaum DJ
    Bioconjug Chem; 2004; 15(6):1264-74. PubMed ID: 15546192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
    Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
    Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
    Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
    Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A; Scripture CD; Trieu V; Williams PJ; De T; Yang A; Beals B; Figg WD; Hawkins M; Desai N
    Clin Cancer Res; 2005 Jun; 11(11):4136-43. PubMed ID: 15930349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.